Maintenance Therapy with Daratumumab ± Pomalidomide Following Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: Results from a Phase 2 Trial

By
Oren Pasvolsky
Bruno Almeida Costa
Yosra M. Aljawai
Krina K. Patel
Qaiser Bashir
Dawen Sui
Samer A. Srour
Mark R. Tanner
Uday R. Popat
Neeraj Y. Saini
Chitra Hosing
Jeremy L. Ramdial
Hans C. Lee
Gregory P. Kaufman
Sheeba K. Thomas
Donna M. Weber
Melody Becnel
Guilin Tang
Robert Z. Orlowski
Richard E. Champlin
Yago Nieto
Elizabeth J. Shpall
Muzaffar H. Qazilbash
September 26, 2026

Blood Cancer Journal

Original Source(s)

Blood Cancer Journal

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

by Oren Pasvolsky, Bruno Almeida Costa, Yosra M. Aljawai, Krina K. Patel, Qaiser Bashir, Dawen Sui, Samer A. Srour, Mark R. Tanner, Uday R. Popat, Neeraj Y. Saini, Chitra Hosing, Jeremy L. Ramdial, Hans C. Lee, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Guilin Tang, Robert Z. Orlowski, Richard E. Champlin, Yago Nieto, Elizabeth J. Shpall, Muzaffar H. Qazilbash
September 26, 2026

Related Content

European Radiology

Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI

World Journal Of Urology

Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment?

by Ingrid Hannestad, Tor Åge Myklebust, Sophie D. Fosså, Stig Muller, Kirsti Aas
September 19, 2026

Baptist Health South Florida

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

by
September 24, 2026
11 min